CA2298474A1 - Procedes et compositions permettant le diagnostic et le traitement de troubles neuropsychiatriques - Google Patents

Procedes et compositions permettant le diagnostic et le traitement de troubles neuropsychiatriques Download PDF

Info

Publication number
CA2298474A1
CA2298474A1 CA002298474A CA2298474A CA2298474A1 CA 2298474 A1 CA2298474 A1 CA 2298474A1 CA 002298474 A CA002298474 A CA 002298474A CA 2298474 A CA2298474 A CA 2298474A CA 2298474 A1 CA2298474 A1 CA 2298474A1
Authority
CA
Canada
Prior art keywords
fsh05
disorder
gene
nucleic acid
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002298474A
Other languages
English (en)
Inventor
Hong Chen
Nelson B. Freimer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2298474A1 publication Critical patent/CA2298474A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

La présente invention concerne le gène fsh05 de mammifaire, nouveau gène associé au trouble bipolaire affectif (BAD) chez les humains. L'invention concerne des acide nucléïques fsh05, des molécules d'ADN recombinantes, des gènes clonés ou des variantes dégénérées de ceux-ci, des produits du gène fsh05, et des anticorps dirigés contre lesdits produits, des vecteurs de clonage contenant des molécules du gène fsh05 de mammifaire, et des hôtes mis au point par génie génétique, destinés à exprimer lesdites molécules. L'invention concerne également des procédés d'identification des composés qui modulent l'expression de fsh05 et l'utilisation de ces procédés comme agents thérapeutiques dans le traitement de troubles provoqués par fsh05 et de troubles neuropsychiatriques. L'invention concerne, en outre, des procédés d'évaluation de diagnostic, de test génétique et de pronostic de troubles provoqués par fsh05 et de troubles neuropsychiatriques comprenant la schizophrénie, le trouble du déficit de l'attention, le trouble schizoaffectif, le trouble bipolaire affectif ou le trouble unipolaire affectif. L'invention concerne également des procédés et des compositions permettant de traiter ces troubles.
CA002298474A 1997-07-22 1998-07-22 Procedes et compositions permettant le diagnostic et le traitement de troubles neuropsychiatriques Abandoned CA2298474A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89808297A 1997-07-22 1997-07-22
US08/898,082 1997-07-22
PCT/US1998/015183 WO1999004825A1 (fr) 1997-07-22 1998-07-22 Procedes et compositions permettant le diagnostic et le traitement de troubles neuropsychiatriques

Publications (1)

Publication Number Publication Date
CA2298474A1 true CA2298474A1 (fr) 1999-02-04

Family

ID=25408913

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002298474A Abandoned CA2298474A1 (fr) 1997-07-22 1998-07-22 Procedes et compositions permettant le diagnostic et le traitement de troubles neuropsychiatriques

Country Status (3)

Country Link
AU (1) AU8580598A (fr)
CA (1) CA2298474A1 (fr)
WO (1) WO1999004825A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897022B2 (en) 1996-03-29 2005-05-24 University Of Miami Susceptability and resistance genes for bipolar affective disorder
WO2001062787A1 (fr) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnostic et traitement de la maladie affective bipolaire
AU2001251668A1 (en) * 2000-04-18 2001-10-30 Millennium Pharmaceuticals, Inc. 39228, a human alcohol dehydrogenase and uses therefor
UA79927C2 (en) * 2000-12-05 2007-08-10 Serono Genetics Inst Sa Polynucleotide, coding a polypeptide of potential-depending portal ionic human channel (canion), polypeptyde, antibody, method for identification of candidate modulator of canion-polypeptyde, method for treatment of bipolar disorder or schizophrenia and use of an antibody for production of drugs for treatment of schizophrenia or bipolar disorder
DE102006018392A1 (de) * 2006-04-20 2007-10-25 Neuroprofile Gmbh Therapeutische Zielmoleküle zur Entwicklung neuartiger Medikamente für degenerative Erkrankungen

Also Published As

Publication number Publication date
WO1999004825A1 (fr) 1999-02-04
WO1999004825A8 (fr) 1999-03-25
WO1999004825A9 (fr) 1999-04-29
AU8580598A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
US6248528B1 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5866412A (en) Chromosome 18 marker
US5955355A (en) Chromosome 18 marker
AU754436B2 (en) Methods and compositions for diagnosing and treating chromosome-18p related disorders
WO2004040016A2 (fr) Marqueurs genetiques
WO1998042362A9 (fr) Procedes et compositions s'appliquant au diagnostique et au traitement des troubles neuropsychiatriques
CA2335378A1 (fr) Methodes et compositions pour le diagnostic et le traitement de troubles du poids corporel, dont l'obesite
US5914394A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5939316A (en) Chromosome 18 marker
CA2298474A1 (fr) Procedes et compositions permettant le diagnostic et le traitement de troubles neuropsychiatriques
EP1068347A1 (fr) Procedes et compositions servant a diagnostiquer et a traiter des maladies neuropsychiatriques
WO1998042723A9 (fr) Procedes et compositions s'appliquant au diagnostique et au traitement des troubles neuropsychiatriques
WO1999035290A1 (fr) Procedes et compositions permettant de diagnostiquer et de traiter des troubles neuropsychiatriques
MXPA00009702A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
WO2001034630A1 (fr) Procedes et compositions servant a diagnostiquer et traiter des troubles associes au chromosome 18q
MXPA00008949A (en) METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18p RELATED DISORDERS
MXPA00009801A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
AU5118399A (en) Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity
WO2001034771A2 (fr) METHODES ET COMPOSITIONS PERMETTANT DE DIAGNOSTIQUER ET DE TRAITER LES TROUBLES LIES AU CHROMOSOME 18q

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20030722